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ANK, Ankyrin; ATRA, All Trans retinoic acid; βmaj, β globin major; βminor, β globin minor; 
BAT8, HLA-B-Associated Transcript 8; BDNF, Brain-derived neurotrophic factor; CA1, Cornu 
ammonis 1; Camk2a, Calcium/calmodulin-dependent protein kinase II alpha; CARM1, 
Coactivator-associated arginine methyltransferase 1; Cdc 14B, CDC14 cell division cycle 14 
homolog B; Cdk 5, Cyclin Dependent Kinase 5; CDP/cut, CCAAT displacement protein/cut 
homolog; CDYL1, Chromodomain Y-Like protein; CEBP β,CCAAT/ Enhancer Binding Protein 
beta; CLBC, Claudin low breast cancer; CSB, Cockayne syndrome group B protein; CSF-2, 
Colony-stimulating factor-2; CST7, Cystatin-7; COMT, Catechol O Methyltransferase; DIM-5, 
Defective In Methylation-5; DNMT1, DNA Methyltransferase 1; Ey, Embryonic  like globin; 
EC, Entorhinal cortex; EMT, Epithelial to mesenchymal; Ep-CAM, Epithelial Cell Adhesion 
Molecule; FosB, FBJ murine osteosarcoma viral oncogene homolog B; Gfi1, Growth factor 
independent 1 transcription repressor; GLP, G9a-like-protein; GR, Glucocorticoid Receptor; 
GRIP1 , Glutamate receptor interacting protein 1; HDAC1, Histone Deacetylase 1; HIV1, 
Human immunodeficiency virus 1; HP1, Heterochromatin Protein; IL6, Interleukin 6; IL8, 
Interleukin 8; JAK2, Janus Kinase 2; JARID 1a, Jumonji, AT rich interactive domain 1; KLF-12, 
Kruppel-Like factor-12; LIF, Leukemia inhibitory Factor; L-LTP, Late phase long-term 
potentiation; LSH, Lymphoid-specific helicase; LTM, Long term memory formation; Magea, 
Melanoma antigen family A, 1; mAM, mouse ATFa-associated Modulator; MHC, Major 
Histocompatibility Complex; MMP-9, Matrix metalloproteinsase-9; Msx1, Msh homeobox 1; 
NAc, Nucleus accumbens; NF-kB, Nuclear Factor Kappa light chain enhancer of activated B 
Cells; NLS, Nuclear localization signals; NRSF, Neuron restrictive silencing factor; PCNA, 
Proliferating cell nuclear antigen; PIC, Pre initiation Complex; PPARγ, Peroxisome proliferator-
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activated receptor gamma; Runx2, Runt-related transcription factor 2; Runx3, Runt related 
transcription factor 3; SAM, S-adenosyl-L-methionine; SASP, Senescent Associated Secretory 
Phenotype; SDF-1, Stromal differentiating factor-1; SET, Su(var)3-9, Enhancer of Zeste, 
Trithorax ; SETDB1, SET domain, bifurcated 1; SETDB2, SET domain, bifurcated 2; Sharp1, 
Enhancer-of-split and hairy-related protein; SIAH1, Seven In Absentia Homolog; SNF2, Sucrose 
NonFermentable 2; TA-CA1, Temporo ammonis–cornu ammonis 1; UHRF1, Ubiquitin-like with 
PHD and ring finger domains 1; WIZ, Widely interspaced zinc finger motifs protein; YY1,Ying 





 Lysine methylation of histone and non-histone substrates by the methyltransferase G9a is mostly 
associated with transcriptional repression. Recent studies, however, have highlighted its role as 
an activator of gene expression through mechanisms that are independent of its methyltransferase 
activity. Here we review the growing repertoire of molecular mechanisms and substrates through 
which G9a regulates gene expression. We also discuss emerging evidence for its wide-ranging 
functions in development, pluripotency, cellular differentiation and cell cycle regulation that 
underscore the complexity of its functions. The deregulated expression of G9a in cancers and 
other human pathologies suggests that it may be a viable therapeutic target in various diseases. 
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G9a structure and activity  
In an attempt to identify genes related to autoimmune disorders in the unexplored regions 
of MHC class III cluster on human chromosome 6, an undefined gene G9a or BAT8 was found 
using a combination of chromosome walking with overlapping cosmid genomic clones and 
pulsed field gel electrophoresis1,2. The human G9a/EHMT2 protein which was initially thought 
to contain 1001 amino acids was later found to lack NG36 transcripts3. Further investigations 
revealed that full length G9a protein (isoform a) is a product of both NG36 (encoded by 4 exons) 
and G9a (encoded by 24 exons) transcripts4 (Fig 1). In addition, a shorter isoform has been 
characterized (isoform b) which lacks exon 10.  The mouse homolog, found on chromosome 17, 
has two alternatively spliced isoforms as well. The long isoform (G9a L) lacks exon 1 and 
includes all of exon 2, while the short isoform (G9a S) contains exon 1 but splices out part of 
exon 2 to result in a N-terminal region resembling the human homolog. A closely related paralog 
GLP/EHMT15 has been identified which exhibits 45% identity with human G9a and differs 
primarily in the N-terminus6.  
G9a belongs to the SET domain containing Su(var)3-9 family of proteins which include 
Suv39h1/h2, SETDB1, SETDB2, and DIM-57–11.  G9a contains an evolutionarily conserved SET 
domain which contributes to its methyltransferase activity, a domain containing ankyrin repeats 
which is involved in protein-protein interactions3,7 and nuclear localization signals that have been 
identified at the N-terminal region12. The catalytic SET domain with variable I-SET insert is 
flanked by pre- and post-SET regions consisting of a pseudo knot. The substrate binding groove 
is formed by I-SET and post-SET domains13  . When transiently expressed, G9a and GLP form 
homomeric and heteromeric complexes via their SET domain; however, endogenously they 
function exclusively as a heteromeric complex in a wide variety of human and mouse cells14.  
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Biochemical studies have revealed that G9a and GLP possess the same substrate 
specificities on histones. Both enzymes have histone 3 (H3)  lysine 9 (K9) methyltransferase 
activity in vitro5,7. G9a transfers methyl groups from S-adenosyl-L-methionine (SAM) to ε-
amino group of the target lysine residue, resulting in mono- and di-methylation of K9 (H3K9me1 
and H3K9me2 respectively), and to a lesser extent, K27of H37. Two tyrosine (Y) residues of G9a 
are of particular importance for catalytic activity and H3K9 di-methylation specificity. Y1154, 
participates in catalysis and Y1067 is involved in hydrogen bonding with the nitrogen atom of 
the ε-amino group of the substrate lysine residue. Loss of Y1154 renders G9a catalytically 
inactive, whereas replacement of Y1067 to phenylalanine allows G9a to tri-methylate H3K9 
(H3K9me3). The proposed model of G9a action involves interaction of the peptide substrate at 
the rigid I-SET domain12. Concurrent binding of SAM at the flexible post-SET domain 
stimulates domain folding and orients the remaining peptide-binding residues. As such the post-
SET domain can “close” onto the substrate to complete the substrate-binding groove and allow 
catalysis to occur. This concurs with the random order of substrate and co-factor binding as 
previously suggested15. Commercially available compounds BIX-01294 and UNC0638 act as 
competitive inhibitors of G9a activity by binding to the substrate binding groove and render it 
inaccessible to substrates16,17. 
Substrate recognition and specificity:  G9a interacts with amino acid residues 6-11 of H3, and  
the minimum substrate recognition criterion in vitro is a seven amino acid heptapeptide with 
RK/ARK consensus e.g. 6-TARKSTG-12 of H318–20.  In the H3 peptide, arginine (R) residue at 
position 8 adjacent to a lysine residue is an absolute requirement for G9a activity; any other 
amino acid substituted at this position abolishes methylation of the H3 peptide substrate. Other 
than the RK specificity, G9a exhibits a preference for hydrophilic amino acids at position 6; 
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smaller amino acids such as alanine (A) are preferred at position 7, whereas hydrophilic and 
hydrophobic amino acids respectively are favoured at positions 10 and 1120. Apart from these 
positional preferences, modification of H3 proximal amino acids serine (S)10 and threonine 
(T)11 by phosphorylation impairs methylation by G9a18,20. In addition to H3, the G9a 
recognition motif is found in several non-histone proteins.  In fact, G9a itself has such a motif at 
its non-catalytic N-terminus which is automethylated18,21. Auto-methylation of K239 (mouse) 
does not result in a loss of its catalytic activity indicating that methylation does not render G9a 
inactive. The auto-methylated G9a peptide resembles tri-methylated H3K9 (H3K9me3). Similar 
to H3K9me3 associated HP1 interaction, auto-methylated G9a peptide interacts with HP1 which 
might stage recruitment of other repressors such as HDAC1 and DNMT118.  G9a also methylates 
other methyltransferases such as mAM, an activator protein of SetDB1, and GLP, suggesting a 
complex internal regulation of these histone methyl transferases18,21. Several additional non-
histone substrates have been identified including WIZ, CDYL1, CSB, ACINUS, HDAC1, 
DNMT1, and KLF1220. While the functional relevance of methylation of non-histone proteins 
has not been established in each case, G9a-mediated methylation of Reptin at K67 under hypoxic 
conditions results in Reptin-dependent inhibition of hypoxia responsive genes, providing a 
mechanism to adjust the cellular response to hypoxia22. Many transcription factors are 
methylated by G9a which appears to negatively impact their transcriptional activity. For 
instance, G9a methylates CEBP β at K39 which interferes with activation of myeloid genes23,24. 
Similarly, MyoD methylation at K104 blocks its transcriptional activity and expression of 
muscle differentiation genes25, and G9a/GLP complex methylates p53 at K373 rendering it 
transcriptionally inactive26. 
Changing partners and switching roles: from repressor to activator 
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Whilst the vast number of studies have implicated its function in mediating H3K9me2 
marks that is associated with transcriptional repression, in erythroid cells, G9a exhibits a more 
complex role in regulating transcription of the human β globin gene27. G9a is recruited to the β 
globin locus in a NF-E2/p45-dependent manner. Interestingly, G9a represses embryonic globin 
Ey expression, whereas it activates the adult β globin βmaj gene. Through pull-down assays 
followed by mass spectrometry, G9a was found to associate with the H3K4 demethylase Jarid1a 
at the embryonic Ey globin promoter resulting in silencing of its expression. On the other hand, 
G9a recruits Mediator only to the βmaj promoter, activating its expression28.  Thus differential 
interaction with Jarid1a and Mediator in distinct co-repressor and co-activator complexes 
accounts for its opposing impact at the Ey and βmaj-globin promoters. Similar to these findings, 
other studies have also reported G9a to act as a co-activator together with GRIP1, CARM1 and 
p300 for nuclear receptors in a methyltransferase activity-independent manner29. G9a is recruited 
by ligand-activated GR bound to GR-binding sites where it functions as a scaffold for 
recruitment of p300 and CARM1 to positively regulate gene expression. The N-terminal region 
of G9a is sufficient to bring about recruitment/stabilization of this activator complex in response 
to dexamethasone treatment30. G9a is also recruited by Runx2 to MMP-9, CSF-2, SDF-1, and 
CST7 promoters to activate their expression independent of its methyltransferase activity31. From 
these studies, it appears that the role of G9a as an activator does not require its methyltransferase 
activity; and suggest its function as a repressor or activator depends upon its interacting partners 
(Fig 2). 
Besides regulation of RNA polymerase II transcription, G9a has also been found to 
regulate RNA polymerase I-mediated transcription. This occurs through interaction of G9a with 
CSB, resulting in H3K9 methylation at the coding region of ribosomal RNAs (rRNAs)32. 
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Moreover, both ATPase activity of CSB and methyltransferase activity of G9a are required for 
association of RNA polymerase I to rDNA. In view of this, a role for G9a has been proposed in 
the inactivation of actively-transcribed rRNAs in preparation for transcriptional re-initiation. 
Function in development and differentiation  
G9a is widely expressed in most tissues including fetal liver, bone marrow, peripheral blood 
leukocytes, thymus, lymph node, spleen and developing skeletal muscles4,33. Loss of G9a in mice 
results in embryonic lethality between embryonic (E) days E9.5-E12.5. Even though no 
abnormalities are seen, G9a-/- embryos at E9.5 morphologically resemble wild type embryos at 
E8.0-E8.5. This growth retardation is attributed to increased apoptosis rather than growth arrest.  
Interestingly, G9a-/- embyronic stem (ES) cells do not show overt growth defects in culture 
conditions, but exhibit severe differentiation defects, suggesting a role for G9a in commitment 
and differentiation34. Consistent with this notion, there is substantial evidence that G9a plays a 
prominent role in early development by repression of Oct-3/4, Nanog and DNMT3L which are 
required for maintenance of pluripotency in ES cells. Thus Oct-3/4 and Nanog expression is 
sustained until E7.5 in G9a-null embryos, indicating the importance of G9a in the silencing of 
pluripotent genes at early differentiation stages35. Post-implantation repression of these 
pluripotency genes is achieved through establishment of methylated H3K9 
heterochromatinization via the SET domain, as well as through de novo DNA methylation by 
recruitment of DNMT3a/3b that associate with the ANK repeats of G9a. The establishment of 
these two separate epigenetic marks prevents reprogramming of ES cells to an undifferentiated 
state. Consistently, in contrast to wild type cells, G9a-/- ES cells differentiated with retinoic acid 
revert back to a pluripotent state by expressing Oct-3/4 and Nanog when re-cultured in LIF-
containing medium36,37. In addition to control of ES cell pluripotency, G9a has also been 
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implicated in genomic imprinting. While G9a is not required for X-chromosome inactivation38, it 
is recruited by non-coding RNAs Kcnq1ot1 and Air to respective target domains in a lineage-
specific manner and stimulate the formation of heterochromatin to cause monoallelic expression 
of specific genes39,40.  
G9a is recruited by LSH, a member of SNF2 family of ATP-dependent chromatin 
remodelling enzymes, to generate normal DNA methylation patterns and stable gene silencing 
during lineage commitment and differentiation of distinct cell types41. Progressive H3K9me2 
patterning occurs in a G9a/GLP dependent manner during lineage specification of hematopoietic 
stem and progenitor cells (HSPCs)42. H3K9me2 marks are deficient in primitive HSCs and are 
formed de novo during lineage commitment, with highest levels in megakaryocytes and T cells. 
Treatment of HSPCs with UNC0638 results in preservation of stem cell-like phenotype and 
function during in vitro expansion. An increase in G9a-mediated H3K9me2 also occurs during 
retinoic acid-induced differentiation of the leukemic cell line HL-60, concomitant with decreased 
JAK2 expression. G9a is recruited to the JAK2 promoter to repress its transcription in a YY1-
dependent manner43. G9a is also important in Th2 cell differentiation. CD4+ T cells from 
conditional knockout mice in which G9a is specifically deleted in T cells fail to differentiate into 
Th2 cells resulting in impaired cytokine production44. 
In contrast to these studies, G9a expression levels and H3K9me2 repression marks 
decline during differentiation of skeletal muscle precursor cells25. Overexpression of G9a in 
myoblasts negatively regulates differentiation, and this is accompanied by elevated H3K9me2 
marks on muscle promoters as well as methylation of MyoD, a key regulator of skeletal 
myogenesis. MyoD methylation inhibits its transcriptional activity and the consequent activation 
of its downstream targets involved in differentiation25,45. Recruitment of G9a to muscle 
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promoters is mediated by the bHLH transcription factor Sharp-1, as well as by the homeoprotein 
Msx133,46. Similar to its impact on skeletal myogenesis, G9a represses differentiation of 
adipocytes, which is dependent upon H3K9me2-mediated inhibition of PPARγ expression. In 
addition, G9a enhances Wnt10b expression, an inhibitor of adipogenesis, in a SET-domain 
independent manner47.  
In the nervous system, G9a/GLP complex functions as master regulator of lineage 
specific gene expression in the brain. Recruitment of G9a by NRSF is important in the repression 
of neuronal genes outside of the nervous system48.  Similarly, conditional ablation of GLP/G9a 
in postnatal neurons of the forebrain using the Camk2a-Cre mice results in expression of early 
neuronal progenitor genes in various regions of the brain49. These changes led to brain 
impairment with reduced exploratory behaviour and locomotor activity, which manifested as a 
mental retardation-like syndrome in adult mice. The phenotype closely resembles human 9q34 
mental retardation syndrome that involves the sub-telomeric deletion of human chromosome 
9(9q34), including the GLP gene. Recently, G9a/GLP were also found to play a role in memory 
consolidation50. Inhibition of GLP/G9a activity with BIX-01294 in the hippocampus disrupted 
LTM formation, and in the EC, enhanced memory consolidation, by increasing expression of 
memory permissive genes. This differential regulation of genes in the hippocampus and EC 
highlights the function of G9a in molecular cross talk between the two brain regions during 
memory consolidation. G9a also plays an important role in cocaine-induced structural and 
behavioural plasticity51. Repeated administration of cocaine decreases G9a mRNA levels and 
global H3K9me2 repressive marks in NAc, resulting in increased gene expression. Repression of 
G9a and H3K9me2 in the NAc neurons promotes cocanine addiction and conversely, its 
overexpression has a reciprocal effect. Together these studies highlight the relevance of 
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H3K9me2 in maintaining transcriptional homeostasis in adult neurons, and underscore the 
function of GLP/G9a in mental retardation, defects in learning, environmental adaptation and 
motivation in mice and humans. 
Role in cellular proliferation, senescence and cancer 
A large body of evidence has indicated a role for G9a in cellular proliferation, 
quiescence, senescence and replication. Recruitment of G9a by CDP/cut, UHRF1 and Gfi1 to the 
p21Cip/Waf1 promoter results in repression of its expression52–54. Consistent with these studies, 
pharmacological inhibition of G9a activity with BIX-01294 reduces proliferation of foetal 
pulmonary arterial smooth muscle cells that is accompanied by G1 cell cycle arrest and elevated 
p21Cip/Waf1 expression. Moreover, migration and contractility was also inhibited with altered 
global methylation levels55. In addition to its role in G1 arrest, G9a was reported to be present in 
a complex with E2F6 and other polycomb group proteins on E2F responsive promoters in G0 
cells5. These studies indicate the involvement of G9a in repression of E2F responsive genes in 
quiescent cells. Similarly, G9a has also been shown to repress HIV1 gene expression and 
maintain quiescence of the latent HIV1 provirus by mediating H3K9me2 on the HIV1 long 
terminal repeat promoter56.  
DNMT1 levels are reduced in senescent cells and knockdown of DNMT1 in human 
diploid fibroblasts correlates with a decrease in G9a/GLP expression. During Ras-induced 
senescence, proteosomal degradation of G9a and GLP occurs through APC/Ccdh1, an ubiquitin 
ligase. Cdc14B and p21 activate APC/Ccdh1, thereby degrading G9a/GLP and causing decreased 
H3K9 di-methylation globally as well as on IL-6 and IL-8 promoters, which are major 
components of senescence-associated secretory phenotype. Knockdown of Cdh1 abolishes IL-6 
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and IL-8 expression in senescent cells, indicating the importance of both G9a/GLP and 
APC/Ccdh1 in senescence57.  
During replication, DNMT1 complexes with G9a at replication foci, coordinating DNA 
and H3K9 methylation, indicating that both molecules work together to restore heterochromatin 
at replication forks during the S phase58. Gene expression analysis performed on G9a conditional 
knockout mouse ESCs revealed a strong correlation between H3K9me2 and late replication 
genes including Magea1 and Dub1a. This study indicates that G9a creates facultative 
heterochromatin by mediating H3K9me2 within late replicating chromatin at the nuclear 
periphery59. Consistent with its role during replication, G9a-/- ESCs exhibited significant delay in 
progression through S phase. Interestingly, G9a mono-methylates H3K56 (H3K56me1), which 
acts as a docking site for PCNA during G1 phase, and thus facilitates PCNA functionality during 
the S phase60.  
Given its role in cellular proliferation, it is not surprising that G9a expression is high in 
many cancers compared to normal tissue. Cancer transcriptome analysis has revealed high G9a 
expression in many tumors including hepatocellular, colon, prostate, lung and invasive 
transitional cell carcinomas, and in B cell chronic lymphocytic leukemia26. In a number of 
human bladder and lung carcinoma patients61, G9a expression is up-regulated. Knockdown of 
G9a in both bladder and lung cancer cell lines causes growth suppression and apoptosis with an 
increase in sub-G1 population. By microarray and chromatin immunoprecipitation experiments 
on G9a knockdown cells, the tumor suppressor SIAH162,63 was identified to be transcriptionally 
regulated by G9a61. Studies on prostate cancer further corroborate the role of G9a in 
carcinogenesis, where downregulation of G9a causes centrosome disruption, chromosomal 
instability, inhibition of cell growth and increased cellular senescence in cancer cells64. G9a is 
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also involved in repression of Runx3 expression which is inactivated in gastric cancer65. In 
Runx3-expressing gastric cell lines, hypoxia increases the accumulation of G9a and H3K9me2 
which leads to Runx3 gene silencing. Overexpression of G9a in gastric cancer cells grown under 
hypoxic conditions leads to further repression of Runx3 expression and deletion of the SET 
domain in G9a results in a failure to repress Runx3 under both normoxic and hypoxic conditions.  
In aggressive lung cancer, high levels of G9a correlate with poor prognosis with 
increased cell migration and invasion in vitro, and metastasis in vivo. The metastatic function of 
G9a in lung cancer is due to repression of Ep-CAM66. Knockdown of G9a in lung cancer cells 
leads to de-repression in Ep-CAM expression and decrease in H3K9me2 levels along with 
reduced levels of DNMT1, HP1 and HDAC1 recruitment at the Ep-CAM promoter.  Similar 
studies in CLBC have uncovered the role of G9a in promoting EMT by repression of E-cadherin 
expression67. Repression of E-cadherin is brought about by the interaction of Snail with G9a 
through its ANK and SET domain. HP1 and other DNA methyltransferases are recruited to the 
E-cadherin promoter required for EMT-induced E-cadherin promoter DNA methylation and 
H3K9me2. Knockdown of G9a reduced H3K9me2 and DNA methylation marks and rescued the 
expression of E-Cadherin, preventing cell migration and invasion in vitro and decreased tumor 
growth and metastatic potential of these cells to colonize the lungs in vivo in CLBC metastasis 
models. Thus by targeting and blocking the association of the Snail-G9a-DNMTs complex, novel 




The abundance of data on G9a and its associated H3K9 methylation activity has led to the 
view that G9a is a co-repressor that silences genes found at euchromatic regions. Nevertheless, 
the fact that G9a has been shown to interact with the Mediator complex and exists in distinct co-
activator complexes highlight a new role for G9a in transcriptional activation. It remains to be 
seen whether, similar to the control of embryonic and adult β-globin expression in differentiating 
erythroid cells, G9a exerts such dual activities on regulation of other cell fate decisions. As such 
more work has to be done to determine the significance of this newly discovered function of 
G9a. Regardless, these studies highlight the importance of elucidating G9a interacting partners 
and relevant complexes that dictate its activity. In addition, the transcription factors that recruit 
G9a to target promoters in various cell types need to be identified.  
The fact that G9a is over-expressed in many different types of cancers, and has been shown 
to be responsible for various aspects of tumorigenesis, including cellular differentiation, 
proliferation and EMT, indicates that G9a may be a feasible target for cancer therapy. This 
supports the prevailing perception that de-regulation of the epigenome in cells is a contributing, 
and possibly causative, factor of oncogenesis. Given its myriad roles, it would also be important 
to investigate the role of G9a in fear-related memory disorders, mental retardation, addictive 
disorders, metabolic disease, as well as skeletal muscle development and regenerative potential. 
This will lead to a greater understanding of the pathologies in which G9a is involved, and, as 
with cancer, the potential for using G9a inhibitors as therapeutic avenues. The efficacy of 
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Figure 1: Schematic representation of G9a domain structure.  Human and mouse G9a 
isoforms are shown with their respective NCBI accession ID (left).  The domain structure was 
constructed using DOG 1.0 software. The Cysteine (Cys) rich region, ankyrin repeats (ANK) and 
the catalytic SET domain with flanking Pre SET and post SET regions are shown. The site for 
methylation (Me),nuclear localization signal (NLS), and the glutamic acid (E) rich region are 
denoted. Numbers indicate amino acid residues.  
Figure 2: Transcriptional repression and activation by G9a. G9a recruitment by transcription 
factors and association with distinct co-factor complexes leads to opposing outcomes on gene 
expression. Transcriptional repression of genes such as myogenin, p21, JAK2 and embryonic β-
globin is dependent on G9a methyltransferase activity (SET domain). On the other hand, G9a 
recruitment by GR, Runx2, and NF-E2/p45 leads to activation of target genes in a SET-domain 
independent manner. This occurs through association of G9a with co-activators such as p300 and 
CARM1, as well as the Mediator complex.  
 
